by FBorchert | Oct 2, 2024 | News
We are extremely proud that our central involvement in designing, execution and analysis of the Telix ZIRCON pivotal phase III study was recently recognised in The Lancet Oncology. This prospective, open-label, multicentre study evaluated the clinical utility of...
by FBorchert | Jun 21, 2024 | News
This summer we welcome our first two trainees. We look forward to seeing them learn and...
by FBorchert | May 16, 2024 | News
We are proud to announce that the dosimetry software QDOSE® designed by us and our development partner Quantinm AB will now become part of a commercial partnership with Telix. Telix intends to integrate the platform into its therapeutic radiopharmaceutical programmes...
by FBorchert | May 10, 2024 | News
Summer 2024 is coming up and as every year we are returning to the SNMMI 2024 in Toronto, Canada on June 8-11. Our two General Managers, Dr. Andreas Kluge and Andreas Fintelmann, and the CEO of ABX-CRO INC, Moritz Kallerhoff, will be there again accompanied by our...
by FBorchert | Feb 26, 2024 | News
This year we will start our conference activities in Santiago, Chile for the 7th Theranostics World Congress. From March 22 to 24 you can find us at booth #A06 and talk with Dr. Andreas Kluge and Andreas Fintelmann, our General Managers, about how ABX-CRO can help you...
by FBorchert | Dec 18, 2023 | News
Prostate cancer awareness month may already be over, but men’s health remains an important topic. We are therefore most pleased to announce that ABX-CRO was chosen to collaborate with Curasight in a phase 2 study to improve the diagnosis of prostate cancer. The...
